The purpose of the present invention is to provide formulation technology with which it is possible to prevent a reduction over time in the kinematic viscosity of an aqueous liquid medicine containing hypromellose and/or hydroxyethyl cellulose. It is possible to prevent a reduction over time in the viscosity of an aqueous liquid medicine compounded by combining hypromellose and/or hydroxyethyl cellulose and polyoxyethylene-hydrogenated castor oil and/or polyoxyl stearate.
